Skip to main content
MyDeficienciesMyDeficiencies
Research Preview — Unreviewed AI Research

Losartan

Angiotensin II receptor blocker (ARB), specifically an AT1 receptor antagonist

Also sold as Cozaar.

Researched 8/29/2026

Evidence summary

Qualifying findings
1
Interactions and timing
1
Searched, nothing found
1
Verified cited sources
3 of 3
Human review
Not yet reviewed
Analyze another medication Medication directory

Overview

Research Preview — Unreviewed AI Research

AI-assisted Research Preview - not yet human-reviewed and not part of Published Knowledge.

This is automated research that has not yet been reviewed by a person. It is not MyDeficiencies published knowledge, it is not medical advice, and it may be incomplete or wrong. It has been added to our editorial review queue.

Angiotensin II receptor blocker (ARB), specifically an AT1 receptor antagonist.

Researched 8/29/2026 · Adversarial review ran: 2 confirmed, 1 scope corrections, 1 rejected.

3 of 3 cited sources were confirmed to exist as described. That check confirms the source is real, not that it supports the claim.

What the research found

Evidence for this exact medication is kept strictly apart from evidence that comes only from its drug class.

Direct evidence for this medication

Measured increase in loss or excretion

Uric acid (serum/urinary)

exact entity

Direct evidence for this medication

Increased loss or excretion of Uric acid (serum/urinary) was reported in people taking Losartan. Increased loss is not itself a measured fall in body stores. The evidence relationship is direct: it was measured in people taking Losartan itself. Discuss with your prescriber before changing anything.

2 cited sources and detail

Human studies that measured this nutrient in people taking this exact medication.

Relationship:
Decrease in serum uric acid; increase in urinary uric acid excretion
Outcome measured:
Measured increase in loss or excretion
Study population:
human studies
Agreement:
3 supporting, 0 contradicting

What was measured: Increased loss or excretion of Uric acid (serum/urinary) was reported in people taking Losartan. Increased loss is not itself a measured fall in body stores.

2 of 2 cited sources were checked and found to support this specific claim. A source existing is not the same as a source supporting the claim.

Why it is here: 2 verified sources were retrieved and confirmed to carry this exact-medication measured result in people. This is a increased loss or excretion, not a nutrient depletion, and it is reported as the measurement it was.

Interactions and timing

How this medication and a nutrient affect each other's absorption, handling or timing. This is not depletion.

Medication and nutrient interaction

Potassium (dietary supplements and salt substitutes)

exact entity

Interaction and timing

An interaction between Losartan and Potassium (dietary supplements and salt substitutes) was reported, affecting absorption, handling or timing. No change in nutrient status is claimed here. This is an interaction between Losartan and Potassium (dietary supplements and salt substitutes), not a measured change in your Potassium (dietary supplements and salt substitutes) status.

1 cited source and detail

How this medication and this nutrient affect each other's absorption, handling or timing. This is not the same as depletion.

Relationship:
Increase in serum potassium risk
Outcome measured:
Medication and nutrient interaction
Study population:
non-human or laboratory models
Agreement:
0 supporting, 0 contradicting

What was measured: An interaction between Losartan and Potassium (dietary supplements and salt substitutes) was reported, affecting absorption, handling or timing. No change in nutrient status is claimed here.

Proposed mechanism: Additive reduction in potassium excretion when RAAS blockade from losartan is combined with exogenous potassium load or potassium-sparing agents. A mechanism explains how an effect could occur. It is not itself a measured clinical outcome.

1 of 1 cited sources were checked and found to support this specific claim. A source existing is not the same as a source supporting the claim.

Why it is here: This is an absorption, binding or timing interaction between the medication and the nutrient, not a measured depletion.

Searched, no supporting evidence found

These relationships were searched for in this research run and no supporting evidence was found. Absence of evidence is not evidence of absence.

Calcium, phosphorus, chloride, sodium

unresolved scope

Searched, no supporting evidence found

No controlled human trial evidence was found in this research run linking losartan to depletion of calcium, phosphorus, chloride, or sodium; only a single unverifiable case report was located, and this does not establish that no effect exists.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: No retrievable source was found for this relationship.

Evidence limitations

What this cannot tell you

  • This is automated research that has not yet been reviewed by a person. It is not MyDeficiencies published knowledge, it is not medical advice, and it may be incomplete or wrong. It has been added to our editorial review queue.
  • Most nutrient-specific human data for losartan (zinc, magnesium) come from a single small research group's study (n=17), limiting generalizability.
  • The uricosuric effect, while well replicated, is specific to losartan and must not be generalized to other ARBs even though losartan is in the ARB class.
All research limitations for this run
  • Case report level evidence for broader electrolyte depletion has not been confirmed in controlled trials and conflicts with the one controlled magnesium study identified.
  • Potassium effects are well established for the ARB class as a whole; exact-medication data (HEAAL, FDA label) support losartan specifically, but individual risk depends heavily on renal function and co-medications not addressed here.
  • 6 of 12 cited sources could not be confirmed to exist as described. Claims resting only on those sources are withheld.
  • Zinc and magnesium human data for losartan derive from one small research group (n=17), limiting generalizability.
  • The uricosuric effect is specific to losartan and must not be generalized to other ARBs.
  • Case report level electrolyte depletion evidence is unconfirmed and conflicts with a controlled magnesium study in this same packet.
  • 5 of 8 sources that were confirmed to exist were not confirmed to support the specific claim they were attached to. Existence is not support, and those claims are withheld.

AI-assisted Research Preview - not yet human-reviewed and not part of Published Knowledge. Educational information only. Not medical advice, diagnosis or treatment. Talk to your prescriber or pharmacist before changing any medication or supplement.

Sources

Only sources attached to information shown above are listed here.

  • Losartan - StatPearls

    2024 · Narrative review · human study

    No public identifier recorded· identifier confirmed to exist (URL)

    https://www.ncbi.nlm.nih.gov/books/NBK526065/

  • Part 1. Uric acid and losartan

    2002 · Narrative review · human study

    PMID 12187310· identifier confirmed to exist (PMID)

    https://pubmed.ncbi.nlm.nih.gov/12187310/

  • Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the RENAAL trial

    2011 · Post-hoc analysis of randomized controlled trial · human study

    PMID 21632472· identifier confirmed to exist (PMID)

    https://pubmed.ncbi.nlm.nih.gov/21632472/
  • Existence of a source and support for a claim are checked separately. A confirmed identifier means the record is real, not that it supports the statement it is cited for.

Questions for your clinician

These are conversation prompts, not findings about you.

  • Could Losartan affect any nutrients over time in my situation?
  • Are there symptoms or risk factors that would make further evaluation appropriate?
  • Could diet, other medications, or health conditions affect this relationship?
  • Would laboratory testing be clinically appropriate for me?
  • Are there medication or supplement interactions I should understand?

Review status

Human review

Published Knowledge is human-reviewed. Research Previews are clearly labeled and have not yet completed human review.

MyDeficiencies is in a free, invitation-only beta. Nothing is for sale here and no payment is taken.

Derived from acceptance run on-demand research run 60c7b5d9-2db3-45d8-9c2b-aec6aa2c6b39 (b2d227fe2bbc).